Shearman & Sterling advised the underwriters in the offering. Mazanti advised Y-mAbs Therapeutics.rY-mAbs Therapeutics, Inc. executed its 2,804,878 shares of common stock at a public offering price…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
